Fred Ramsdell

2025 Nobel Laureate
Founder
Sonoma Biotherapeutics

Fred Ramsdell, Ph.D., is a veteran biotechnology leader in immunology with over three decades of experience. Fred is a founder of Sonoma Biotherapeutics and until recently served as Chief Scientific Officer. Immediately prior to Sonoma, Fred was the CSO at the Parker Institute for Cancer Immunotherapy (PICI) where he helped build and advance multiple research programs from the inception of the Institute.

He earned his BS degree from the University of California, San Diego and his doctoral degree in microbiology and immunology from the University of California, Los Angeles. He then completed a fellowship at the NIH and subsequently joined Immunex. He later joined Darwin Molecular (acquired by Celltech, Inc) where his team’s efforts included the discovery of FOXP3, the key factor for regulatory T cell development and activity. The discovery was awarded the 2017 Crafoord Prize and the 2025 Nobel Prize in Physiology or Medicine. Fred has also held leadership positions at ZymoGenetics and Novo Nordisk and currently sits on various Scientific Advisory Boards and Grant Review agencies.